Skip to main content

Advertisement

SpringerLink
Log in

Impact of Clinical Characteristics and Management on the Prognosis of Unselected Heart Failure Patients

  • ORIGINAL ARTICLE
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Purpose

Heart failure (HF) is a major public health issue. This study conducted a real-life analysis of the impact of clinical characteristics and medical management of HF on its prognosis.

Methods

Analysis was based on the EGB (“Echantillon Généraliste des Bénéficiaires”) database. A cohort comprising 1825 adult patients with a first admission for HF between 2009 and 2011 was created and followed until June 2013 (median 22.3 [7.7–34.5] months) for survival analysis.

Results

Mean age was 77.3 ± 13.2 years (53 % ≥80 years). The overall incidence of HF admission was 117 [112–122] per 100,000 population with a marked increase in patients >80 years (1297 [1217–1348]). At discharge, only 8 % of patients received recommended combination of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB), beta-blockers (BB) and mineralocorticoid receptor antagonists (MRA). Only prescription levels of BB and vitamin K antagonists, at discharge, increased during the study period. In-hospital mortality was 9 % and survival was 71.6 %[69.5–73.6] and 52.0 %[49.4–54.6] at 12 and 36 months, respectively. In multivariate analysis, female gender [HR:0.78 (0.67–0.91), p = 0.001], ACEi/ARB + BB + MRA [0.41 (0.28–0.60), p < 0.001] and ACEi/ARB + BB [0.47 (0.39–0.57) p < 0.001] treatments were associated with improved survival, conversely to age 70–79 [1.90 (1.20–3.00), p = 0.003] and ≥80 [3.50 (2.30–5.40), p < 0.001], cardiogenic shock [3.00 (2.10–4.40), p < 0.001], acute pulmonary edema [1.70 (1.10–2.50), p = 0.01], denutrition [1.80 (1.45–2.24), p < 0.001], dilated cardiomyopathy [1.20 (1.00–1.40), p = 0.02] and in-hospital acute renal failure [1.36 (1.05–1.78), p = 0.002].

Conclusions

These real-life HF data provide insight into prognostic factors and “real-world” pharmacological management in this unselected HF population, confirming the benefit of ACEi/ARB + BB ± MRAs on patient survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993;22:6A–13A.

    Article  CAS  PubMed  Google Scholar 

  2. Delahaye F, Roth O, Aupetit JF, de Gevigney G. Epidemiology and prognosis of cardiac insufficiency. Arch Mal Coeur Vaiss. 2001;94:1393–403.

    CAS  PubMed  Google Scholar 

  3. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.

    Article  PubMed  Google Scholar 

  4. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KKL, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402.

    Article  PubMed  Google Scholar 

  5. Laribi S, Aouba A, Nikolaou M, Lassus J, Cohen-Solal A, Plaisance P, et al. Trends in death attributed to heart failure over the past two decades in Europe. Eur J Heart Fail. 2012;14:234–9.

    Article  PubMed  Google Scholar 

  6. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart failure survey programme– a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–63.

    Article  CAS  PubMed  Google Scholar 

  7. Martin-Latry K, Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010;19:256–65.

    Article  PubMed  Google Scholar 

  8. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58:286–90.

    Article  CAS  PubMed  Google Scholar 

  9. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, et al. Insulin glargine and risk of cancer: a cohort study in the French national healthcare insurance database. Diabetologia. 2012;55:644–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Bezin J, Pariente A, Lassalle R, Dureau-Pournin C, Abouelfath A, Robinson P, et al. Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France. Eur J Clin Pharmacol. 2014;70:429–36.

    Article  CAS  PubMed  Google Scholar 

  11. Dupouy J, Fournier J-P, Jouanjus É, Palmaro A, Poutrain J-C, Oustric S, et al. Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns–a cohort study. Eur Neuropsychopharmacol. 2014;24:192–9.

    Article  CAS  PubMed  Google Scholar 

  12. Fournier A, Zureik M. Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmacoepidemiol Drug Saf. 2012;21:343–51.

    Article  PubMed  Google Scholar 

  13. Bongue B, Laroche ML, Gutton S, Colvez A, Guéguen R, Moulin JJ, et al. Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French national insurance healthcare system. Eur J Clin Pharmacol. 2011;67:1291–9.

    Article  CAS  PubMed  Google Scholar 

  14. Duong M, Salvo F, Pariente A, Abouelfath A, Lassalle R, Droz C, et al. Usage patterns of « over-the-counter » vs. prescription-strength nonsteroidal anti-inflammatory drugs in France. Br J Clin Pharmacol. 2014;77:887–95.

    Article  PubMed  Google Scholar 

  15. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239–41.

    Article  Google Scholar 

  16. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.

    Article  PubMed  Google Scholar 

  17. Malek MH, Berger DE, Coburn JW. On the inappropriateness of stepwise regression analysis for model building and testing. Eur J Appl Physiol. 2007;101:263–4. author reply 265–6.

    Article  PubMed  Google Scholar 

  18. Logeart D, Isnard R, Resche-Rigon M, Seronde M-F, de Groote P, Jondeau G, et al. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail. 2013;15:465–76.

    Article  PubMed  Google Scholar 

  19. Tuppin P, Cuerq A, de Peretti C, Fagot-Campagna A, Danchin N, Juillière Y, et al. First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up. Arch Cardiovasc Dis. 2013;106:570–85.

    Article  PubMed  Google Scholar 

  20. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The euroheart failure survey programme–a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464–74.

    Article  CAS  PubMed  Google Scholar 

  21. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW, ADHERE. Scientific advisory committee and investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from acute decompensated heart failure national registry (ADHERE). Am Heart J. 2007;153:1021–8.

    Article  PubMed  Google Scholar 

  22. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119:515–23.

    Article  PubMed  Google Scholar 

  23. Yeung DF, Boom NK, Guo H, Lee DS, Schultz SE, Tu JV. Trends in the incidence and outcomes of heart failure in Ontario, Canada: 1997 to 2007. CMAJ. 2012;184:E765–73.

  24. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Komajda M, Hanon O, Hochadel M, Lopez-Sendon JL, Follath F, Ponikowski P, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: euro heart failure survey II. Eur Heart J. 2009;30:478–86.

    Article  PubMed  Google Scholar 

  26. Zannad F, Briancon S, Juilliere Y, Mertes PM, Villemot JP, Alla F, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. Epidémiologie de l’insuffisance cardiaque avancee en lorraine. J Am Coll Cardiol. 1999;33:734–42.

    Article  CAS  PubMed  Google Scholar 

  27. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More « malignant » than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315–22.

    Article  CAS  PubMed  Google Scholar 

  28. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.

    Article  PubMed  Google Scholar 

  29. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77.

    Article  CAS  PubMed  Google Scholar 

  30. Oluleye OW, Rector TS, Win S, McMurray JJ, Zile M, Komajda M, et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014.

  31. Güder G, Frantz S, Bauersachs J, Allolio B, Wanner C, Koller MT, et al. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail. 2009;2:563–71.

    Article  PubMed  Google Scholar 

  32. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.

    Article  CAS  PubMed  Google Scholar 

  33. Gissi-HF I, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–9.

    Article  Google Scholar 

  34. Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–38.

    Article  CAS  PubMed  Google Scholar 

  35. Cowburn PJ, Cleland JG, Coats AJ, Komajda M. Risk stratification in chronic heart failure. Eur Heart J. 1998;19:696–710.

    Article  CAS  PubMed  Google Scholar 

  36. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European society of intensive care medicine (ESICM). Eur Heart J. 2008;29:2388–442.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Mr. Pierre Pothier for the editing of this manuscript.

Conflict of Interest

None

Author information

Authors and Affiliations

  1. Clermont Université, ISIT-CaVITI, BP 10448, 63001, Clermont-Ferrand, France

    Romain Eschalier, Guillaume Clerfond, Charles Vorilhon, Géraud Souteyrand, Pascal Motreff & Jean-René Lusson

  2. Cardiology Department, CHU Clermont-Ferrand, 63003, Clermont-Ferrand, France

    Romain Eschalier, Arab Yalioua, Guillaume Clerfond, Charles Vorilhon, Bernard Citron, Frédéric Jean, Géraud Souteyrand, Pascal Motreff & Jean-René Lusson

  3. Pharmacology Department, CHU Clermont-Ferrand, 63003, Clermont-Ferrand, France

    Chouki Chenaf, Nicolas Authier & Alain Eschalier

  4. Biostatistics Unit (Clinical Research and Innovation Direction), CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France

    Aurélien Mulliez & Bruno Pereira

Authors
  1. Romain Eschalier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chouki Chenaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aurélien Mulliez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arab Yalioua
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guillaume Clerfond
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicolas Authier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Charles Vorilhon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bernard Citron
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bruno Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Frédéric Jean
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Géraud Souteyrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Pascal Motreff
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Alain Eschalier
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jean-René Lusson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Romain Eschalier.

Additional information

Romain Eschalier and Chouki Chenaf are both first co-authors; Alain Eschalier and Jean-René Lusson are both last co-authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eschalier, R., Chenaf, C., Mulliez, A. et al. Impact of Clinical Characteristics and Management on the Prognosis of Unselected Heart Failure Patients. Cardiovasc Drugs Ther 29, 89–98 (2015). https://doi.org/10.1007/s10557-015-6572-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-015-6572-y

Keywords

Search

Navigation